Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

This study has been terminated.
(Dr. Amy Law left Geisinger Health System. 4 patients enrolled)
Genentech, Inc.
Information provided by (Responsible Party):
Geisinger Clinic Identifier:
First received: September 9, 2008
Last updated: October 10, 2012
Last verified: October 2012
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent

Condition Intervention Phase
Head and Neck Cancer
Drug: Erlotinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer

Resource links provided by NLM:

Further study details as provided by Geisinger Clinic:

Primary Outcome Measures:
  • One year disease free [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 2 years ]

Enrollment: 4
Study Start Date: September 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Drug: Erlotinib
150 mg per day orally until disease progression occurs, up to a maximum of 12 months
Other Name: Tarceva


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Stage III, IV SCCHN
  • Completed curative treatment

Exclusion Criteria:

  • Prior chemotherapy or radiotherapy
  • Recurrent disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00750555

United States, Pennsylvania
Geisinger Health System
Danville, Pennsylvania, United States, 17822
Sponsors and Collaborators
Geisinger Clinic
Genentech, Inc.
Principal Investigator: Amy Law, MD Geisinger Clinic
  More Information

Additional Information:
Responsible Party: Geisinger Clinic Identifier: NCT00750555     History of Changes
Other Study ID Numbers: 2008-0153
Study First Received: September 9, 2008
Last Updated: October 10, 2012

Keywords provided by Geisinger Clinic:
squamous cell cancer of head and neck

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 24, 2017